401 related articles for article (PubMed ID: 23679326)
1. Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha.
Dirican A; Kucukzeybek Y; Erten C; Somali I; Demir L; Can A; Payzin KB; Bayoglu IV; Akyol M; Yildiz Y; Koeseoglu M; Alacacioglu A; Tarhan MO
Asian Pac J Cancer Prev; 2013; 14(3):2101-5. PubMed ID: 23679326
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
3. The association of hematologic parameters on the prognosis of patients with metastatic renal cell carcinoma.
Dirican A; Kucukzeybek Y; Somali I; Erten C; Demir L; Can A; Bahriye Payzin K; Vedat Bayoglu I; Akyol M; Koseoglu M; Alacacioglu A; Oktay Tarhan M
J BUON; 2013; 18(2):413-9. PubMed ID: 23818354
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
Yuasa T; Tsuchiya N; Urakami S; Horikawa Y; Narita S; Inoue T; Saito M; Yamamoto S; Yonese J; Fukui I; Nakano K; Takahashi S; Hatake K; Habuchi T
BJU Int; 2012 May; 109(9):1349-54. PubMed ID: 21883864
[TBL] [Abstract][Full Text] [Related]
5. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer.
Heng DY; Chi KN; Murray N; Jin T; Garcia JA; Bukowski RM; Rini BI; Kollmannsberger C
Cancer; 2009 Feb; 115(4):776-83. PubMed ID: 19127560
[TBL] [Abstract][Full Text] [Related]
6. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma.
Keizman D; Ish-Shalom M; Huang P; Eisenberger MA; Pili R; Hammers H; Carducci MA
Eur J Cancer; 2012 Jan; 48(2):202-8. PubMed ID: 22018713
[TBL] [Abstract][Full Text] [Related]
7. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
[TBL] [Abstract][Full Text] [Related]
8. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
[TBL] [Abstract][Full Text] [Related]
9. Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.
Rautiola J; Utriainen T; Peltola K; Joensuu H; Bono P
Acta Oncol; 2014 Jan; 53(1):113-8. PubMed ID: 23721300
[TBL] [Abstract][Full Text] [Related]
10. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
Tsimafeyeu I; Zart JS; Chung B
BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.
Pilskog M; Beisland C; Akslen LA; Bostad L; Haug Å; Heinrich D; Hjelle KM; Straume O
BMC Urol; 2017 Aug; 17(1):74. PubMed ID: 28859644
[TBL] [Abstract][Full Text] [Related]
12. Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.
Négrier S; Bushmakin AG; Cappelleri JC; Korytowsky B; Sandin R; Charbonneau C; Michaelson MD; Figlin RA; Motzer RJ
Eur J Cancer; 2014 Jul; 50(10):1766-1771. PubMed ID: 24768571
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J
Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of Systemic Inflammatory Biomarkers in Patients with Metastatic Renal Cell Carcinoma.
Nader Marta G; Isaacsson Velho P; Bonadio RRC; Nardo M; Faraj SF; de Azevedo Souza MCL; Muniz DQB; Bastos DA; Dzik C
Pathol Oncol Res; 2020 Oct; 26(4):2489-2497. PubMed ID: 32583330
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of hematologic parameters in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors.
Gunduz S; Mutlu H; Uysal M; Coskun HS; Bozcuk H
Asian Pac J Cancer Prev; 2014; 15(8):3801-4. PubMed ID: 24870797
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy.
Takagi T; Fukuda H; Kondo T; Ishihara H; Yoshida K; Kobayashi H; Iizuka J; Okumi M; Ishida H; Tanabe K
Target Oncol; 2019 Apr; 14(2):179-186. PubMed ID: 30927174
[TBL] [Abstract][Full Text] [Related]
17. First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†.
Ravaud A; Oudard S; De Fromont M; Chevreau C; Gravis G; Zanetta S; Theodore C; Jimenez M; Sevin E; Laguerre B; Rolland F; Ouali M; Culine S; Escudier B
Ann Oncol; 2015 Jun; 26(6):1123-1128. PubMed ID: 25802238
[TBL] [Abstract][Full Text] [Related]
18. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Grünwald V; Lin X; Kalanovic D; Simantov R
Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
[TBL] [Abstract][Full Text] [Related]
19. Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.
Harmon CS; DePrimo SE; Figlin RA; Hudes GR; Hutson TE; Michaelson MD; Négrier S; Kim ST; Huang X; Williams JA; Eisen T; Motzer RJ
Cancer Chemother Pharmacol; 2014 Jan; 73(1):151-61. PubMed ID: 24220935
[TBL] [Abstract][Full Text] [Related]
20. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Ruiz-Morales JM; Swierkowski M; Wells JC; Fraccon AP; Pasini F; Donskov F; Bjarnason GA; Lee JL; Sim HW; Sliwczynsk A; Ptak-Chmielewska A; Teter Z; Beuselinck B; Wood LA; Yuasa T; Pezaro C; Rini BI; Szczylik C; Choueiri TK; Heng DY
Eur J Cancer; 2016 Sep; 65():102-8. PubMed ID: 27487293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
